To examine the incidence of arrhythmias in dipyridamole infusion and the relation between dipyridamole-induced arrhythmias and ST-segment depression, dipyridamole electrocardiography tests were performed on 100 patients with coronary artery disease. Dipyridamole was infused at a rate of 0.568mg/kg for 4min, and 87-lead body surface mapping was performed to determine ischemic ST-segment depression. Positive ischemic response was defined as 0.10mV horizontal or downsloping ST-segment depression below the baseline, lasting 80msec after the J point. Arrhythmias were observed by continuous electrocardiographic monitoring using a CM-5 lead electrocardiography. With respect to ventricular premature contractions (VPC), a group of patients with previous myocardial infarction (MI group) had a significantly higher incidence than a group of patients without previous myocardial infarction (non-MI group) before (16.7% vs. 1.7%, p<0.01) and after (38.1% vs. 3.4%, p<0.005) the dipyridamole infusion. The incidence of supraventricular premature contractions (SVPC), however, was not significantly different between the MI and non-MI groups. A group of patients with positive ischemic response had a significantly higher incidence of SVPC after the dipyridamole infusion than a group of patients with negative ischemic response (p<0.005). However, there was no significant difference in the incidence of VPC between the negative and positive ischemic response groups. These results suggest that dipyridamole-induced VPC is not always associated with ischemic ST-segment depression, but dipyridamoleinduced SVPC is associated with dipyridamole-induced ischemic ST-segment depression in patients with coronary artery disease.
. Incidence of arrhythmias in patients with previous myocardial infarction and in patients without previous myocardial infarction. The incidence of VPC in a MI group was significantly higher than that of a non-MI group before (p<0.01) and after (p<0.005) dipyridamole infusion. However, the incidence of SVPC was not significantly different between the 2 groups. VPC=ventricular premature contraction; SVPC=supraventricular premature contraction; MI=previous myocardial infarction.
tween the 2 groups. The incidences of VPC and SVPC before and after dipyridamole infusion were compared with each other. The incidence of VPC in the MI group and the incidence of SVPC in the non-MI group after the dipyridamole infusion were significantly higher than those before the dipyridamole infusion (p<0.05 and p<0.005, respectively). On the other hand, the incidence of VPC in the non-MI group and the incidence of SVPC in the MI group after the dipyridamole infusion were not significantly higher than those before the dipyridamole infusion. The incidence of positive ischemic response of the non-MI group was significantly higher than that of the MI group (46.6% vs. 19.0%, p<0.005, respectively). Figure 2 shows the incidence of arrhythmias in patients with coronary artery disease based on negative or positive ischemic response. There was no significant difference in the incidence of VPC between the 2 groups. On the other hand, the incidence of SVPC after the dipyridamole infusion for the positive ischemic response group was significantly higher than that for the negative ischemic response group (p<0.005). However, there were no significant differences between the 2 groups in the incidence of SVPC before and during the dipyridamole infusion. Incidence of arrhythmias in patients with coronary artery disease based on negative or positive ischemic response. There were no significant differences in the incidence of VPC between the 2 groups. On the other hand, the incidence of SVPC after dipyridamole infusion for the positive ischemic response group was significantly higher than that for the negative ischemic response group (p<0.005). However, there were no significant differences between the 2 groups in the incidence of SVPC before and during dipyridamole infusion. VPC=ventricular premature contraction; SVPC= supraventricular premature contraction; Neg=negative ischemic response; Pos =positive ischemic response; NS=not significant.
DISCUSSION
Intravenous dipyridamole has been reported to provoke angina and myocardial ischemia because of its coronary vasodilative effect.20) Therefore, the dipyridamole infusion test has recently become widely used for the diagnosis of CAD. Some investigators1),2),10) have reported that cardiac arrhythmias do not occur in the dipyridamole infusion. There have been few studies of the incidence of dipyridamole-induced arrhythmias in patients with CAD.7),8) However, detailed information about the occurrence of dipyridamole-induced arrhythmias in relation to ischemic response or myocardial infarction is not known. The purpose of this study was 1) to examine the incidence of arrhythmias in the dipyridamole infusion, and 2) to investigate the relation between dipyridamole-induced arrhythmias and ischemic ST-segment depression in the dipyridamole electrocardiography test.
Dipyridamole-induced ventricular premature contraction Goldshlager et al21), 22) have reported that myocardial ischemia is one of the causes of exercise-induced VPC in patients with CAD. On the other hand, it has been reported that the infusion of dipyridamole induces myocardial ischemia in patients with CAD.3)-6),9),11),12) If dipyridamole induces ischemia, it may also induce VPC. Concerning the incidence of VPC and ischemic response (Fig. 2) , the positive group for ischemic response did not have a significantly higher incidence than the negative group. These results suggest that the dipyridamole-induced VPC is not always associated with myocardial ischemia. In this study, the incidence of VPC in the MI group was significantly higher than that of the non-MI group before (p<0.01) and after (p<0.005) dipyridamole infusion (Fig. 1) . It is thought that the higher incidence of VPC in the MI group (Fig. 1 ) may be associated with wall motion abnormalities or left ventricular dysfunction.2),3)
Dipyridamole-induced supraventricular premature contraction To our knowledge, few previous studies7) have reported the incidence of SVPC in dipyridamole infusion. In this study, there was no significant difference between the MI and non-MI groups in the incidence of SVPC in the dipyridamole infusion. However, the incidence of SVPC in the non-MI group tended to be higher than that in the MI group (Fig. 1) . In Fig.  2 , the positive ischemic response group had a higher incidence of SVPC after dipyridamole infusion than the negative ischemic response group (p<0.005). These results suggest that the dipyridamole-induced SVPC may be associated with myocardial ischemia. However, the precise mechanism of the dipyridamole-induced SVPC remains unknown and further investigation will be necessary.
Limitations
In this study, ischemic ST-segment depression in the dipyridamole electrocardiography test was considered to be a positive ischemic response indicating myocardial ischemia. However, ischemic ST-segment depression does not always reflect myocardial ischemia. Thus, the dipyridamole-induced arrhythmias are related to ischemic ST-segment depression, but not always to myocardial ischemia.
Conclusion
We evaluated the incidence of dipyridamole-induced arrhythmias in patients with CAD. It was demonstrated that dipyridamole-induced VPC is not always associated with ischemic ST-segment depression, but that dipyridamole-induced SVPC is associated with ischemic ST-segment depression in patients with CAD.
